XML 51 R36.htm IDEA: XBRL DOCUMENT
v3.21.2

Earnings per share | 12 Months Ended
--- | ---
Jun. 30, 2021
Text block [abstract] |
Earnings per share | Note 31. Earnings per share
|  | 2021 A$’000 |  |  | 2020 A$’000 |  |  | 2019 A$’000 |
Loss after income tax attributable to the owners of Kazia Therapeutics Limited |  |  | (8,422 | ) |  |  | (12,467 | ) |  |  | (10,270 | )
Loss after income tax attributable to the owners of Kazia Therapeutics Limited |  |  | (8,422 | ) |  |  | (12,467 | ) |  |  | (10,270 | )
|  | Number |  |  | Number |  |  | Number |
Weighted average number of ordinary shares used in calculating basic earnings per share |  |  | 117,674,543 |  |  |  | 73,053,514 |  |  |  | 57,503,555 |
Weighted average number of ordinary shares used in calculating Diluted earnings per share |  |  | 117,674,543 |  |  |  | 73,053,514 |  |  |  | 57,503,555 |
|  | Cents |  |  | Cents |  |  | Cents |
Basic earnings per share |  |  | (7.16 | ) |  |  | (17.07 | ) |  |  | (17.86 | )
Diluted earnings per share |  |  | (7.16 | ) |  |  | (17.07 | ) |  |  | (17.86 | )
1,865,000 unlisted convertible notes with a face value of A$464,000 and 4,446,500 unlisted options have been excluded from the above calculations as they were antidilutive.

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 33 -IssueDate 2020-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfEarningsPerShareExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block [abstract] + References No definition available. + Details
Name: | kzia_TextBlockAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration